Systemic infection with Histoplasma capsulatum induced a granulomatous inflammatory response in the lymphoreticular organs of C57BL/6 mice that was associated with elevated levels of angiotensin-converting enzyme (ACE) 
Systemic infection with Histoplasma capsulatum induced a granulomatous inflammatory response in the lymphoreticular organs of C57BL/6 mice that was associated with elevated levels of angiotensin-converting enzyme (ACE) in the spleens. To determine the influence of ACE on the granulomatous response, either captopril or MK 421, two inhibitors of ACE, were administered intraperitoneally to mice 6 h after intravenous injection of H. capsulatum and then daily for 1 week. Each ACE inhibitor sharply reduced ACE activity in the spleens of infected mice. Both drugs worsened the clinical severity of infection and significantly increased the growth of H. capsulatum in livers and spleens of mice infected for 1 week. The histopathological changes in mice given captopril were more severe, with massive infiltrates of macrophages in proximity to large aggregates of yeasts. Conversely, the administration of captopril for 2 weeks during the resolving phases of infection did not slow the healing of the granulomatous lesions, nor did it provoke a relapse of infection. Captopril did not promote the growth of H. capsulatum in artificial medium. This drug was not cytotoxic to peripheral blood leukocytes or to splenic leukocytes from normal and infected mice. Administration of captopril to normal mice for 1 Angiotensin-converting enzyme (ACE) is an exopeptidase that converts angiotensin I to angiotensin II and inactivates bradykinin (17, 26) . ACE activity is elevated in the sera of some individuals with granulomatous diseases, including sarcoidosis (6) , berylliosis (12) , leprosy (11) , and histoplasmosis (18) . Furthermore, increased ACE activity has been detected within granuloma-containing lymph nodes of patients with sarcoidosis (24) and in granulomas from livers, colons, ilea, and lungs of mice experimentally infected with Schistosoma mansoni (29) .
At present, the biological significance of increased ACE activity in these granulomatous diseases is unknown. However, recent reports have suggested that ACE may be involved in the regulation of granulomatous inflammation. Thus, the administration of captopril, a specific inhibitor of ACE, to mice with schistosomiasis reduces ACE activity and the volumes of the egg-induced granulomas in the livers, gastrointestinal tracts, and lungs (29) . Likewise, captopril substantially diminishes the granulomatous inflammatory response in the lungs and spleens of mice given an intravenous (i.v.) inoculum of heat-killed Mycobacterium bovis BCG (21 Howard (30) ; peritoneal macrophages were harvested with RPMI 1640 medium containing 10 U of heparin per ml from mice inoculated i.p. 3 days previously with 2 ml of 10% Proteose Peptone (Difco). The macrophages were washed and then suspended in RPMI 1640 medium containing 10% fetal calf serum and 0.1% gentamicin to a final concentration of 106 cells per ml; 1-ml portions were placed on 25-mm round glass cover slips in 35-mm plastic dishes and incubated for 2 h at 37°C. The dishes were then washed extensively, and the peritoneal macrophages were incubated with captopril or medium for 3 h. Subsequently, the macrophage monolayers were inoculated with 2 x 105 yeast cells. The extracellular yeast cells were removed after 1 h, and cover slips from each group were removed and stained with Diff-Quik (Dade Diagnostic Inc., Aquada, P.R.). The remaining monolayers were incubated for an additional 15 (2) .
Statistics. The Wilcoxon rank sum test was used to determine levels of significance between groups.
RESULTS
Effect of captopril on ACE activity in spleens from H. capsulatum-infected mice. Captopril or saline was adminis-tered i.p. 6 h after i.v. inoculation of 6 x 105 yeast-phase H. capsulatum cells, and treatment was continued daily for 1 week. As shown in Table 1 , the ACE activity in extracts of spleens was significantly higher (P < 0.01) after 1 week of infection compared with normal mice. Treatment with captopril (150 mg/kg per day) significantly reduced the ACE activity in spleens of infected mice compared with untreated, infected controls (P < 0.01). Lower dosages of captopril (75 and 25 mg/kg per day) also significantly diminished ACE activity in the spleens of infected mice (P < 0.05).
Captopril worsens the clinical severity of infection. Captopril, given as described above, greatly intensified the severity of clinical disease in mice compared with infected mice that received placebo treatment with saline. Signs of infection (i.e., inactivity, weight loss, and ruffled fur) appeared earlier (day 4) in mice given captopril than in infected mice given saline (day 7). By day 7 of infection, 70% of the infected captopril recipients were severely ill. Indeed, by day 10 90% of mice given captopril were dead, compared with none of the control, infected mice. Administration of the same captopril regimen to age-matched, normal mice produced no clinical illness. Furthermore, both gross and histological examinations of tissues were normal. In other studies, infected mice were given captopril in dosages of 75 or 25 mg/kg per day. These animals also manifested greater severity of illness than infected controls given saline; however, there were no deaths in the infected mice given captopril or in the control infected mice after 10 days.
Captopril increases growth of H. capsulatum yeast cells in (Fig. 1B) . Captopril (75 mg/kg per day) also significantly increased the number of H. capsulatum yeast cells cultured from the livers and spleens of infected mice (P < 0.05 for both); even at a dosage of 25 mg/kg per day, it significantly enhanced the growth of H. capsulatum in spleens (P < 0.05) (Fig. 1B) .
The weights of livers (1.3 + 0.07 g) and spleens (0.195 + 0.13 g) from infected mice given the highest dosage of captopril did not differ (P > 0.05) from the weights of livers (1.25 ± 0.07 g) and spleens 0.228 + 0.35 g) from saline recipients. Thus, the increases in number of H. capsulatum colony-forming units recovered from the livers and spleens of captopril recipients cannot be explained by organomegaly.
To test the possibility that captopril may have enhanced the recovery of H. capsulatum by acting directly upon the organism to promote growth, 100 budding yeast cells were dispensed onto plates containing either BHIA/B medium (see above) or BHIA/B medium supplemented with captopril (200 pg/ml) and incubated at 30°C for 7 to 10 days. In three separate experiments, the recovery from the plates containing BHIA/B medium alone was 34 ± 2 CFU (mean + standard error of the mean) whereas 28 + 2 CFU was recovered from the plates containing BHIA/B medium plus captopril. Clearly, captopril did not enhance the growth of H. capsulatum.
Effect of MK 421 on ACE activity in spleens and on recovery of H. capsulatum. MK 421 is a specific ACE inhibitor that is chemically distinct from captopril and lacks a sulfhydryl moiety (16) . To determine whether this ACE inhibitor could exert inimical effects similar to those caused by captopril administration, 25 mg of MK 421 per kg per day was given to mice 6 h after injection of H. capsulatum yeast cells and then daily for 1 week. The mean ACE activity in the spleens of mice given this drug was significantly lower (P < 0.05) and the activity in the spleens of control infected mice (Table 1) MK 421 also worsened the clinical status of infected mice and significantly increased the number of yeast cells recovered from the livers (P = 0.01) and spleens (P < 0.05) compared with infected controls (Fig. 2) . Thus, two chemically different inhibitors of ACE impaired host defense mechanisms against H. capsulatum during acute phases of infection.
Histopathology of spleens. Histopathological examination of blind-coded specimens of spleens from infected mice given saline or captopril (150 mg/kg per day) provided clear evidence of more severe disease in the latter group. In mice given saline, the red pulp was heavily infiltrated by macrophages; as described previously (1), marginal zones and periarteriolar lymphocyte sheaths of the white pulp were invaded by well-demarcated infiltrates of these cells (Fig.  3A) . Scattered yeast cells (15 to 20 cells per high-power field) were present in both the red and white pulp (Fig. 3B) . In striking contrast, the granulomatous lesions within spleens of mice given captopril were far more extensive and less well circumscribed (Fig. 3C) . There was extensive disruption of malpighian corpuscles by poorly organized, granulomatous infiltrates in which foci of karyorrhexis were numerous. These areas of karyorrhexis appeared not to be caused by the death of rapidly dividing lymphocytes since we detected no differences in the number of pyroninophilic lymphocytes (5 to 10 lymphocytes per high-power field) in the spleens of mice given captopril or saline.
In all sections of spleens from captopril-treated animals, periodic acid-Schiff stain revealed macrophages (two to four per high-power field) engorged with yeasts, a phenomenon that did not occur in infected controls. In addition, large aggregates of yeast cells (75 to 125 cells per high-power field) were present throughout the red and white pulp areas (Fig.  3D) . Spleens from infected mice given MK 421 also demonstrated more extensive granulomatous inflammation than did controls, with disruption of the white pulp areas and increased numbers of yeast cells.
Since ACE inhibitors modified the inflammatory response to H. capsulatum during acute stages of infection, we examined the evolution of this response after completion of captopril administration. Thus, we performed studies on mice inoculated with H. capsulatum and then given either Thus, the adverse effect of captopril on cell-mediated defenses against H. capsulatum appears to be lost rapidly after cessation of drug administration, and subsequent maturation of an "effective" inflammatory response is not delayed substantially.
Is captopril cytotoxic or immunosuppressive? Drugs that are cytotoxic for lymphocytes and macrophages or otherwise suppress cell-mediated immunity may enhance susceptibility to infection with H. capsulatum (5, 27) . The possibility that captopril might have such properties was explored by giving 150 mg/kg per day to normal and infected mice for 1 week and counting the leukocytes in the peripheral blood and in the spleens. The drug did not alter the absolute counts of leukocytes and lymphocytes in the peripheral blood of normal mice compared with saline-injected controls (Table  2) . Likewise, it did not change the total number of splenocytes or the total number of splenic lymphocytes and macrophages. In mice infected for 1 week, there is a lymphopenia in the peripheral blood and increased splenic cellularity (1). Captopril did not worsen the lymphopenia of the blood, nor did it alter the splenic cellularity in infected mice ( Table 2) .
The effects of captopril on the in vitro and in vivo cellular immune responses of mice inoculated with H. capsulatum could not be studied since these responses are depressed profoundly during the first 3 weeks of infection (1). Therefore, the drug (150 mg/kg per day) was given to normal mice for 1 week, and the mice were then sacrificed to measure blastogenic responses by splenocytes to concanavalin A and phytohemagglutinin. In three experiments, the response to concanavalin A by cells from control mice was 78,853 + 5,670 cpm (mean + standard error of the mean), compared with a response of 69,293 + 5,002 cpm by cells from captopril recipients. The response to phytohemagglutinin by splenocytes from normal mice (24,986 + 3,205 cpm) was greater than, but not significantly different (P > 0.05) from, the response by cells from mice given captopril (22,915 ± 2,145 cpm). The background activity of unstimulated spleen cell cultures from both groups of mice ranged from 122 to 318 cpm.
To determine whether captopril could modify the delayedtype hypersensitivity response, normal mice were sensitized to SRBC and then challenged in the footpads with SRBC 5 days later. The increase in footpad swelling of animals given the drug (37 + 2.8%) was similar to that of mice given saline (35 ± 1.7%). Furthermore, the banal inflammatory responses of unimmunized mice that were footpad challenged with SRBC alone did not differ between saline recipients (9.0 + 1.8%) and captopril recipients (8.0 ± 1.7%). Thus, captopril does not appear to be cytotoxic, nor does it act as a nonspecific immunosuppressant in the assay systems which we used.
Captopril does not alter intracellular growth of H. capsulatum. Macrophages are the principal effector cells that mediate resistance to H. capsulatum (8) . In preliminary experiments, we determined that captopril did not impair phagocytosis of H. capsulatum yeast cells by normal murine peritoneal macrophages (data not shown). Subsequently, two experiments were performed to determine whether captopril augmented intracellular growth of H. capsulatum (see above). At 15 h after macrophages were infected with H. capsulatum, the number of intracellular yeast cells had increased from 2.6 ± 0.1 cells at zero time to 5.6 ± 0.2 cells, with a generation time of 13.6 ± 1 h. The number of yeast cells in macrophages that were exposed continuously to 200 jig of captopril per ml increased from 2.8 ± 0.1 to 6.4 ± 0.2 cells, with a generation time of 15.2 ± 0.8 h. Thus, in vitro captopri did not promote intracellular growth of H. capsulatum.
Can captopril administration reactivate a latent H. capsulatum infection? After i.v. inoculation of 6 x 105 yeast cells the number of H. capsulatum colony-forming units recoverable from livers and spleens decreases progressively after day 7; by week 8 less than 3,000 CFU can be recovered from these organs in 18% of mice (1) . Therefore, to determine whether captopril could reactivate disease during recovery from systemic infection, 150 mg of captopril per kg per day was given i.p. for 2 weeks to mice that had been inoculated with H. capsulatum 6 weeks previously. A second group of 6-week-infected mice was given cortisone acetate (50 mg/kg per day), and a third group received saline for 2 weeks. The animals were then sacrificed, and the livers and spleens from each group were cultured for H. capsulatum. Yeast cells were not recovered from the spleens of eight captopriltreated mice. However, low numbers of yeasts (<200 CFU) were cultured from the spleens of two of eight cortisonetreated mice and from the spleens of two of four saline recipients. Low numbers of yeasts were recovered from the livers of two of six captopril-treated mice, five of eight cortisone-treated mice, and two of six saline controls. There were no histological differences between the inflammatory responses in spleens from mice given the drug and spleens 
DISCUSSION
This study demonstrated that systemic infection of C57BL/ 6 mice with the dimorphic fungus H. capsulatum induces a granulomatous inflammatory response in the lymphoreticular system which is associated with elevated levels of ACE activity in the spleens. Our results complement and extend previous reports that ACE levels are elevated in the sera, pulmonary lavage fluids, and tissues of experimental animals and some humans with various granulomatous diseases (3, 21, 24, 29) .
In infected mice treated for 1 week with captopril or MK 421, there appeared to be poor inhibition of H. capsulatum yeast cell multiplication, as indicated both by the large numbers of mononuclear phagocytic cells that were filled to capacity with intact yeast cells and by the significantly increased number of H. capsulatum colony-forming units cultured from the spleens of these animals. Concomitantly, there was massive infiltration by macrophages in the spleens of mice given either ACE inhibitor compared with spleens from control infected mice. Therefore, this response may represent an ongoing cellular response that is ineffectual and is secondary to impairment of effector mechanisms by ACE inhibitors.
When captopril was administered to mice during the resolving phase of infection (6 to 8 weeks), it did not impede healing of the granulomatous lesions in the spleens, nor did it increase the recovery of yeast cells from the livers and spleens. Therefore, it appears that the immunomodulatory effects of ACE inhibitors are dependent upon the phase of the cell-mediated immune response during which they are given. More specifically, granulomatous inflammation may be susceptible to alteration by ACE inhibitors only when the response is developing acutely rather than during later stages of resolution.
There are several possible mechanisms by which ACE inhibitors might favor the growth of H. capsulatum within macrophages. First, ACE inhibitors may impair directly the capacity of macrophages to inhibit replication of H. capsulatum. However, the results of our studies on the growth of H. capsulatum within normal macrophages that were continuously exposed to captopril suggest that this hypothesis is unlikely.
Since captopril did not augment the number of H. capsulatum colony-forming units per organ in a dose-dependent fashion a second possibility is that the heightened severity of infection induced by captopril could be explained by an effect of the drug unrelated to its ACE inhibitory activity. Alternatively, it has been reported that angiotensin II, the principal biological product of ACE, can depress intracellular killing of Candida albicans by rat macrophages at concentrations ranging from 10-6 to 10-4 M (7). However, these concentrations of angiotensin II are 103-to 105-fold greater than the levels in the sera of humans (23) or rats (13) given captopril. Thus, it is unlikely that angiotensin II impairs the growth-inhibitory activity of macrophages against Histoplasma.
Finally, captopril may alter the ability of macrophages to inhibit the growth of H. capsulatum by increasing the production of prostaglandins (22) and bradykinin (23) . These inflammatory mediators are agonists of adenylate cyclase and can depress the macrophage function by activating intracellular cyclic 3',5'-adenosine monophosphate (15) . Furthermore, the action of prostaglandins may be potentiated by the increased level of bradykinin since this mediator promotes prostaglandin release (9, 14) . Whether (29) . In addition, it reduces the intensity of granulomatous inflammation evoked in the lungs of mice by i.v. inoculation of heat-killed M. bovis BCG (20 
